Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gatsuciclib · AZD-8421

Small molecule · Inhibitor of cyclin-dependent kinase 2 (CDK2) · developed by ASTRAZENECA

Phase 1/2 Most advanced trial
AZN Developer

What is Gatsuciclib?

Gatsuciclib is an orally bioavailable small molecule that selectively binds and inhibits cyclin-dependent kinase 2 (CDK2), a serine/threonine kinase that regulates cell cycle progression. Inhibition of CDK2 is intended to cause cell cycle arrest and apoptosis in tumor cells. It is being studied in ER+ HER2- advanced breast cancer and high-grade serous ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD-8421
Drug type
Small molecule
Targets
cyclin-dependent kinase 2 (CDK2)
Mechanism
Inhibitor of cyclin-dependent kinase 2 (CDK2)
Pathways
cell cycle progression, apoptosis, tumor cell proliferation
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
43UHD9M2ME

Conditions studied

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)

Other drugs acting on CDK2

More from ASTRAZENECA

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Gatsuciclib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.